Saturday, September 18, 2021
wellness India Expo
Home Tags DCGI

Tag: DCGI

Wait over as DCGI approves Bharat Biotech & Serum Institute COVID-19...

After adequate examination, Central Drugs Standard Control Organisation decided to accept the recommendations of the Expert Committee, and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in an emergency situation

Enough compliances in place during COVID-19 vaccine development, assures regulator

Drugs Controller General of India has assured that the COVID-19 vaccines being developed and tested in India have followed all the right methodologies as per existing regulatory guidelines........................

Zydus seeks approval to commence Phase III clinical trials of its...

New Delhi: Zydus Cadila has announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe, well tolerated and immunogenic in...

Biological E begins clinical trials of its COVID-19 vaccine

The results of this clinical trial are expected to be available by February 2021..................

Are India’s pharma regulations denting patient safety?

Experts shed light on the cause of rising Vitamin C prices and why patients end up paying a higher price for basic affordable vitamins which were otherwise available at reasonable prices earlier......................

Jubilant launches JUBI-R, its generic version of COVID-19 drug remdesivir in...

Jubilant Generics, a subsidiary of Jubilant Life Sciences has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection)........................

DCGI nod to Serum Institute for conducting human trials of Oxford...

The Drugs Controller General of India has given the Serum Institute of India a green light to conduct phase 2 and 3 human trials of the Oxford-AstraZeneca COVID-19 vaccine candidate in India..................

Mylan secures DCGI approval for its drug-resistant TB drug, Pretomanid

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years. The approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance..................

Biophore ramps up Made-In-India Favipiravir production for Covid-19

Hyderabad-based Biophore India Pharmaceuticals has received the DCGI license to manufacture the API in India and has been cleared for export as well.................

Bharat Biotech’s COVID-19 vaccine ‘COVAXIN’ gets DCGI nod, human trials to...

Human trials of India’s first indigenous experimental vaccine against COVID-19, COVAXIN, developed by Bharat Biotech is set to begin across India in July........................